不可切除III期非小细胞肺癌伴驱动基因组变异患者的度伐利尤单抗巩固治疗
多中心回顾性研究纳入2015年4月至2020年10月欧美26中心接受放化疗后度伐利尤单抗治疗的不可切除III期非小细胞肺癌患者323例,其中43例携带驱动基因组变异。全队列中位无进展生存期17.5个月,中位总生存期47个月;驱动基因组变异组与非变异组中位无进展生存期无显著差异,但KRASm G12C、EGFRm del19/ex21与BRAFm V600E/ALKr亚组间中位无进展生存期差异有统计学意义。
要点
- 驱动基因组变异组与非变异组中位无进展生存期无显著差异:14.9个月 vs 18个月(P=1.0)。
- KRASm G12C中位无进展生存期未达到,EGFRm del19/ex21为8.1个月,BRAFm V600E/ALKr为7.8个月(P=0.02)。
- 作者认为EGFR/BRAF突变及ALK重排患者度伐利尤单抗巩固治疗活性有限,KRASm患者则不然。
核心结论
- 在不可切除III期非小细胞肺癌中,度伐利尤单抗巩固治疗对携带EGFR/BRAF突变和ALK重排的患者活性有限,但对KRASm患者未观察到同样有限的活性。
- 作者指出需要更大规模的前瞻性研究来证实这些发现。
研究设计与样本
- 多中心回顾性研究,纳入2015年4月至2020年10月在欧美26个中心接受放化疗后度伐利尤单抗治疗的不可切除III期非小细胞肺癌患者。
- 共纳入323例患者,其中43例携带一种驱动基因组变异:KRASm 26例(8例G12C)、EGFRm 8例(6例del19/ex21)、BRAFm 5例(4例V600E)、ALKr 4例。
- 驱动基因组变异包括EGFR/BRAF/KRAS突变和ALK/ROS1重排;基于驱动基因组变异评估无进展生存期和总生存期。
主要发现
- 全队列中位无进展生存期为17.5个月(95%CI 13.2-24.9),中位总生存期为47个月(95%CI 47-未达到)。
- 驱动基因组变异组与非变异组中位无进展生存期无统计学显著差异:14.9个月(95%CI 8.1-未达到) vs 18个月(95%CI 13.4-28.3)(P=1.0)。
- 亚组分析中位无进展生存期:KRASm G12C未达到(95%CI 11.3-未达到),EGFRm del19/ex21为8.1个月(95%CI 5.8-未达到),BRAFm V600E/ALKr为7.8个月(95%CI 7.7-未达到)(P=0.02)。
- 患者中位年龄66岁(范围39-84),性别比1:1,98%体能状态评分0-1,19%不吸烟,88%为腺癌,PD-L1阳性85%(缺失4例)。
局限性
- 原文指出需要更大规模的前瞻性研究来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Durvalumab is the standard-of-care as consolidation therapy after chemo-radiotherapy in stage III unresectable non-small cell lung cancer (NSCLC); however, its activity across patients with NSCLC harbouring driver genomic alterations (dGA) is poorly characterised. MATERIAL AND METHODS: Multicentre retrospective study including patients with stage III unresectable NSCLC treated with durvalumab after chemo-radiotherapy between April 2015 and October 2020 at 26 centres in Europe and America. Clinical and biological data were collected; dGA included: EGFR/BRAF/KRAS mutations (m) and ALK/ROS1 rearrangements (r). We evaluated progression-free survival (PFS) and overall survival (OS) based on dGA. RESULTS: Out of 323 patients included, 43 patients had one dGA: KRASm (n = 26; 8 G12C), EGFRm (n = 8; 6 del19/ex21), BRAFm (n = 5; 4 V600E) and ALKr (n = 4). The median age was 66 years [39-84], gender ratio 1:1, with 98% performance status (PS) 0-1 and 19% non-smokers; 88% had adenocarcinoma. PD-L1 was positive in 85% (n = 4 missing). In the whole cohort, the median PFS was 17.5 months (mo.) (95% CI, 13.2-24.9) and median OS 47 mo (95%CI, 47-not reached [NR]). No statistically significant differences in terms of the median PFS were observed between patients with dGA vs. non-dGA: 14.9 mo (95% CI, 8.1-NR) vs. 18 mo. (95% CI, 13.4-28.3) (P = 1.0); however, when analysed separately: the median PFS was NR (11.3-NR) in the KRASm G12C vs. 8.1 mo (5.8-NR) in the EGFRm del19/ex21 vs. 7.8 mo (7.7-NR) in the BRAFm V600E/ALKr (P = 0.02). CONCLUSIONS: We observed limited activity of durvalumab consolidation in patients with stage III unresectable NSCLC with EGFR/BRAFm and ALKr but not for those harbouring KRASm. Larger prospective studies are needed to confirm these findings.
引用
- Riudavets M, Auclin E, Mosteiro M, et al. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. Eur J Cancer. 2022. PMID: 35307254. doi:10.1016/j.ejca.2022.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。